Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Autologous Cell Therapy Market Size, Share, and Outlook - Growth Analysis and Forecast, 2026-2035 | CAR-T and Personalized Oncology Fuel 19.40% CAGR to USD 54.83 Billion

globenewswire.com
AZN AstraZeneca is advancing its anti BCMA x CD19 CAR T therapy, AZD0120, following its acquisition of Gracell, indicating pipeline innovation and expansion in the autologous cell therapy market. GILD Gilead Sciences is mentioned as a prominent market participant in the autologous cell therapy sector, suggesting its involvement and potential growth in this area. JNJ Johnson & Johnson (Janssen Biotech, Inc) is listed as a prominent participant in the autologous cell therapy market, indicating its presence and potential in this growing sector. BMY Bristol Myers Squibb is identified as a prominent market participant in the autologous cell therapy sector, suggesting its ongoing involvement and potential in this expanding field. VERI Vericel Corporation is mentioned as a prominent participant in the autologous cell therapy market, indicating its presence and potential in this growing sector. LCTX Lineage Cell Therapeutics, Inc. is listed as a prominent market participant in the autologous cell therapy sector, suggesting its involvement and potential for growth.

Autologous Cell Therapy Market Size, Share, and Outlook - Growth Analysis and Forecast, 2026-2035 | CAR-T and Personalized Oncology Fuel 19.40% CAGR to USD 54.83 Billion Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- "Autologous Cell Therapy Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)" has been added to ResearchAndMarkets.com's offering.

The global autologous cell therapy market was valued at USD 9.31 Billion in 2025 and is projected to reach USD 54.83 Billion by 2035, expanding at a CAGR of 19.40% during the forecast period of 2026-2035. Market growth is supported by rising demand for personalized treatments, increasing cancer prevalence, advances in cell processing technologies and the expanding clinical success of patient-derived therapies.

Key Market Insights

Autologous Cell Therapy Market Growth Drivers

The growing adoption of personalized medicine and regenerative therapies is strengthening the global autologous cell therapy market outlook. Increasing cases of cancer, autoimmune diseases, blood disorders and musculoskeletal conditions are creating demand for advanced patient-specific treatments. Favorable regulatory frameworks, investment in research and development, and improvements in cell collection, processing, expansion and storage are also supporting wider clinical use.

CAR T therapies remain a major growth driver, particularly in oncology. In July 2025, the European Commission authorized obe cel (obecabtagene autoleucel) for relapsed/refractory B ALL. The authorization expanded access to personalized CAR T treatment and reinforced confidence in autologous cellular immunotherapies. Improved clinical outcomes, broader treatment indications and more efficient manufacturing processes are expected to support continued market expansion.

Autologous Cell Therapy Market Trends

Pipeline innovation is reshaping the competitive landscape. In January 2026, AstraZeneca advanced its anti BCMA x CD19 CAR T therapy, AZD0120, following its acquisition of Gracell. Development activity involving dendritic cell therapy, NK cell therapy autologous approaches and next-generation personalized oncology programs is broadening the range of potential applications.

Manufacturers are increasingly focused on reducing production turnaround times, improving scalability and strengthening treatment center networks. Strategic acquisitions, partnerships and commercialization agreements are helping companies expand technical capabilities and geographic reach. Continued investment in precision therapeutics and advanced manufacturing infrastructure is expected to improve patient access while supporting pipeline progression.

Market Segmentation

The autologous cell therapy market is segmented by therapy into autologous stem cell therapy and autologous cellular immunotherapies. By source, the market includes bone marrow, epidermis and other sources. Major applications include oncology, musculoskeletal disorders, blood disorders, autoimmune diseases and other indications.

Key end users include hospitals, research centres, cancer treatment centres and other healthcare organizations. The regional market covers North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Oncology Maintains the Leading Application Share

Oncology dominated the market with an estimated 88.55% share during the historical period. The segment benefits from the growing use of CAR-T autologous therapies, advances in cell expansion and sustained development of targeted cancer treatments. Regulatory approvals and favorable clinical outcomes continue to reinforce oncology's leading position.

Autologous cellular immunotherapies are forecast to account for approximately 97% of the market by therapy. Their dominance is linked to commercial success in oncology, expanding indications, regulatory progress and increasing investment from pharmaceutical and biotechnology companies. Autologous stem cell therapies are expected to retain a smaller share while contributing to regenerative medicine and selected disease applications.

North America Leads the Regional Market

North America held more than 57% of the autologous cell therapy market during the historical period. The region's leadership is supported by advanced healthcare infrastructure, established leukapheresis capabilities, strong research funding and a mature regulatory environment. Investments in specialized manufacturing facilities and treatment centers further support the delivery of personalized cell therapies at scale.

Europe remains an important market due to regulatory activity, academic research networks and the presence of established cell therapy developers. Asia Pacific also presents growth opportunities as regional companies expand regenerative medicine portfolios, manufacturing capacity and clinical development programs.

Leading Autologous Cell Therapy Companies

Sanpower Group, through Dendreon Pharmaceuticals LLC., maintains a significant oncology presence with Provenge, a dendritic cell therapy for prostate cancer. The company continues to invest in patient-specific immunotherapies, processing infrastructure and commercialization capabilities.

Holostem Terapie Avanzate S.r.l. develops epithelial stem cell therapies for burns, rare diseases and genetic disorders. Its academic collaborations and cell expansion expertise support its position in the European personalized cell therapy market.

Novartis AG has a strong autologous therapy portfolio led by its CAR-T autologous platform, including Kymriah. Its global research, leukapheresis, manufacturing and commercialization networks support continued development in oncology.

Tego Science focuses on regenerative medicine, advanced wound care, skin applications and autologous treatments using patient-derived cells. The company is expanding through cell processing innovation and efficient manufacturing turnaround.

Other prominent market participants include Gilead Sciences, Johnson & Johnson (Janssen Biotech, Inc), Bristol Myers Squibb, CORESTEM, Inc., Vericel Corporation, Opexa Therapeutics, Lineage Cell Therapeutics, Inc., Pharmicell Co., Inc., and GC Biopharma (GC Cell).

Market Outlook

The autologous cell therapy market is positioned for substantial growth through 2035 as oncology demand, clinical pipeline development and personalized medicine investment accelerate. Companies that improve manufacturing efficiency, secure regulatory approvals and expand treatment access are expected to be best placed to capitalize on the projected 19.40% CAGR.

For more information about this report visit https://www.researchandmarkets.com/r/w50c0a

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.